BioNTech SE Reports Q2 2024 Financial Results

TL;DR

BioNTech dropped its Q2 2024 earnings report on Aug 5th. Check the filing for details.

AI Summary

On August 5, 2024, BioNTech SE announced its second quarter 2024 financial results. The company is a biopharmaceutical firm focused on infectious diseases, cancer, and other serious illnesses. This filing is a Form 6-K report, which typically includes financial results and other material information for foreign private issuers.

Why It Matters

This report provides investors with BioNTech's latest financial performance, offering insights into the company's operational health and progress in its drug development pipeline.

Risk Assessment

Risk Level: low — This is a routine financial results filing (6-K) and does not contain new material events or significant changes.

Key Players & Entities

• BioNTech SE (company) — Registrant
• August 5, 2024 (date) — Date of press release and filing

FAQ

From the Filing

0001776985-24-000066.txt : 20240805 0001776985-24-000066.hdr.sgml : 20240805 20240805063226 ACCESSION NUMBER: 0001776985-24-000066 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20240805 FILED AS OF DATE: 20240805 DATE AS OF CHANGE: 20240805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241173060 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kq22024earningsprear.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On August 5, 2024, BioNTech SE (the “Company”) issued a press release announcing its second quarter 2024 financial results and corporate update and details of a conference call to be held at 8:00 am EDT on August 5, 2024 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein. The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: August 5, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Se cond Quarter 2024 Financial Results and Corporate Update 99.2 Second Quarter 2024: Corporate Update and Financial Results EX-99.1 2 a991bntxq22024pressrelease.htm EX-99.1 Document Exhibit 99.1 BioNTech Announces Second Quarter 2024 Financ ial Results and Corporate Update • Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 • Launched updated variant-adapted COVID-19 vaccine in the European Union (“EU”), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application (“sBLA”) with the United States Food and Drug Administration (“U.S. FDA”) • Reiterates guidance for total revenues in the range of €2.5-3.1 billion • Reports second quarter 2024 revenues